MPM BioImpact’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

MPM BioImpact’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-351,350	Closed	-$9.43M	–	41
2022 Q1	$9.43M	Buy	351,350 +80,000	+29%	+$2.69M	2.53%	9
2021 Q4	$12.9M	Hold	271,350	–	–	2.36%	10
2021 Q3	$18M	Buy	271,350 +2,164	+0.8%	+$154K	2.8%	12
2021 Q2	$21M	Hold	269,186	–	–	3.45%	9
2021 Q1	$25.5M	Sell	269,186 -39,500	-13%	-$4.7M	3.2%	8
2020 Q4	$37.6M	Hold	308,686	–	–	6.61%	6
2020 Q3	$27M	Hold	308,686	–	–	6.5%	7
2020 Q2	$19.9M	Hold	308,686	–	–	5.3%	8
2020 Q1	$13.8M	Buy	+308,686	New	+$16.4M	8.42%	5

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

MPM BioImpact's TPTX Position: Q2 2022 in Review

MPM BioImpact sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 351,350 shares — an estimated $9.43M sold.

MPM BioImpact first reported a position in TPTX in Q1 2020 and held it in 9 quarters. The position peaked at $37.6M in Q4 2020. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

MPM BioImpact reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
MPM BioImpact sold 351,350 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $9.43M.
MPM BioImpact first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 9 quarters.
MPM BioImpact's Turning Point Therapeutics, Inc. Common Stock position peaked at $37.6M in Q4 2020.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on MPM BioImpact's 13F filing for Q2 2022, filed 11 Aug 2022.